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Criteria for the diagnosis of corticobasal
degeneration
ABSTRACT
Current criteria for the clinical diagnosis of pathologically confirmed corticobasal degeneration (CBD)
no longer reflect the expanding understanding of this disease and its clinicopathologic correlations. An
international consortium of behavioral neurology, neuropsychology, and movement disorders special-
ists developed new criteria based on consensus and a systematic literature review. Clinical diagnoses
(early or late) were identified for 267 nonoverlapping pathologically confirmed CBD cases from pub-
lished reports and brain banks. Combined with consensus, 4 CBD phenotypes emerged: corticobasal
syndrome (CBS), frontal behavioral-spatial syndrome (FBS), nonfluent/agrammatic variant of primary
progressive aphasia (naPPA), and progressive supranuclear palsy syndrome (PSPS). Clinical features
of CBD cases were extracted from descriptions of 209 brain bank and published patients, providing
a comprehensive description of CBD and correcting common misconceptions. Clinical CBD pheno-
types and features were combined to create 2 sets of criteria: more specific clinical research criteria
for probable CBD and broader criteria for possible CBD that are more inclusive but have a higher
chance to detect other tau-based pathologies. Probable CBD criteria require insidious onset and grad-
ual progression for at least 1 year, age at onset $50 years, no similar family history or known tau
mutations, and a clinical phenotype of probable CBS or either FBS or naPPA with at least 1 CBS
feature. The possible CBDcategory uses similar criteria but has no restrictions on age or family history,
allows tau mutations, permits less rigorous phenotype fulfillment, and includes a PSPS phenotype.
Future validation and refinement of the proposed criteria are needed. Neurology 2013;80:496–503
GLOSSARY
AD 5 Alzheimer disease; AOS 5 apraxia of speech; CBD 5 corticobasal degeneration; CBS 5 corticobasal syndrome; CJD 5
Creutzfeldt-Jakob disease; cr-CBD 5 clinical research criteria for probable corticobasal degeneration; DLB 5 dementia with
Lewy bodies; FTD 5 frontotemporal dementia; FTLD-TDP 5 frontotemporal lobar degeneration with TDP-43 immunoreactive
inclusions; GRN 5 granulin; p-CBD 5 possible corticobasal degeneration criteria; PD 5 Parkinson disease; PNFA 5 progressive
nonfluent aphasia; PPA5 primary progressive aphasia;PSP5 progressive supranuclear palsy; PSPS5 progressive supranuclear
palsy syndrome.
When first described, “corticodentatonigral degeneration with neuronal achromasia” was consid-
ered a distinct clinicopathologic entity,1 eventually termed corticobasal degeneration (CBD).2
Clinicopathologic studies have since revealed that the originally described clinical features of
CBD, now called corticobasal syndrome (CBS), are often due to other pathologies. As a pathologic
diagnosis, CBD is characterized by widespread deposition of hyperphosphorylated 4-repeat tau in
neurons and glia, the latter as astrocytic plaques, in specific topographic areas.3 Despite various
clinical diagnostic criteria (table e-1 on the Neurology® Web site at www.neurology.org),4–10 the
pathology of CBD is predicted antemortem in only 25% to 56% of cases.11–17 Additionally, while
these clinical criteria continue to be widely applied and cited, they reflect CBS alone and not the
more recently recognized behavioral presentations of CBD.
From the University of Maryland (M.J.A., S.G.R., W.J.W.), Baltimore; University of California San Diego (I.L.), San Diego; Morton and Gloria
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Definition and standardization of clinical
diagnostic criteria for CBD are critical, especially
as potential neuroprotective therapies for tauopa-
thies emerge. In light of advances in the under-
standing of CBD, we used specialist consensus,
brain bank cases, and a critical literature review
to develop new diagnostic criteria. During this
process, however, it became clear that clinico-
pathologic heterogeneity of CBD confounds
the development of specific criteria, unlike what
has been accomplished for other neurodegenera-
tive diseases. Thus, we propose 2 sets of criteria:
a narrower, more specific one for probable CBD
and a broader set for possible CBD that has less
specificity for CBD pathology while still repre-
senting probable tau-based pathology.
METHODS Previous CBD clinical diagnostic criteria were re-
viewed. Invited international specialists in behavioral neurology,
neuropsychology, and movement disorders met on October
14–15, 2009, and based on participants’ experience and literature
reviews, clinical phenotypes were identified and CBD criteria
were drafted.
Subsequently, a systematic literature search and later update using
MEDLINE (1950 to April 2012) and EMBASE (1980 to April
2012) identified English-language pathologically proven CBD series.
Search terms included “corticobasal,” “corticobasal degeneration,”
and “CBD” text word searches paired with “pathology” as a MeSH
search term and text word search. Inclusion criteria were 1)
a minimum of 5 pathologically proven CBD cases (chosen a priori
to avoid the bias toward atypical cases from case reports) and 2)
extractable data for clinical phenotype, symptoms/features, or both.
Only patients with pathologically proven CBD were included. Inclu-
sion criteria were intentionally broad to enable a large sample size and
decrease the impact of ascertainment bias and variations in CBD
feature reporting. Information was entered into a database including
commonly reported features and those deemed relevant by the panel.
Publication authors and institutions were cross-checked to prevent
case duplication. Additionally, 5 centers with CBD brain bank cases
provided data on published and unpublished cases. When available,
the original brain bank data were abstracted rather than using the less
comprehensive information from brain bank–related publications.
Two overlapping sets of cases were developed: cases for which features
of CBD could be extracted and cases for which information was
available regarding clinical diagnosis or phenotype.
Clinical features were recorded at 2 time parameters, at presenta-
tion and “ever” (during the disease course), variables for which the
most consistent data could be abstracted. Presentation was a mean of
3.0 (SD 1.9) years after symptom onset in one series.18 When data
were abstracted, features were considered as present or absent only if
specifically described. While this approach carries the risk of over-
estimating the frequency of each feature, it was thought suitable due
to the complexity of CBD and the varying degrees of detail in the
retrospective data. Because of this approach, the denominator for
calculating the frequency of any given clinical feature is less than
the total number of cases identified, reflecting the number of cases
for which that feature was reported. Finally, a literature search was
conducted for clinicopathologic correlation articles including CBD
subjects and cases with other proven pathologies to identify specific
clinical features that might improve the accuracy of proposed CBD
criteria vs other pathologic diagnoses. Results of the specialist panel,
case reviews, and clinicopathologic studies were integrated into the
proposed criteria. A glossary of terms is available in appendix e-1.
RESULTS Previous clinical diagnostic criteria. While
self-described as criteria for CBD, previous diagnostic
criteria (table e-1)4–10 outline the clinical features now
labeled CBS, reflecting an asymmetric movement disor-
ders presentation combined with lateralized higher cor-
tical features. Consideration of the role of dementia in
diagnostic criteria exemplifies changes in our under-
standing of CBS and CBD. Previous clinical criteria
excluded “early dementia” to increase diagnostic speci-
ficity,19 but dementia is now recognized as a presenting
and predominant feature in many cases of CBD.13,15,20
Systematic literature review. Of 808 nonoverlapping
articles identified in the systematic literature search,
37 met inclusion criteria. Clinical features were available
for 103 published13,15,16,18,21–24 and 106 brain bank non-
overlapping CBD cases. Brain bank case information
was provided by Mayo Clinic Rochester (22 patients,
K. Josephs, personal communication, 2011), University
of Western Ontario (8 patients, A. Kertesz and
P. McMonagle, personal communication, 2011), Uni-
versity of California San Francisco (20 patients, S.E.
Lee, personal communication, 2011), and Mayo Clinic
Jacksonville (53 patients, D.W. Dickson, personal com-
munication, 2011). Information on 3 unpublished cases
was provided by University of Pennsylvania (P. Moore
and M. Grossman, personal communication, 2011),
supplementing their 15 published cases.15
Clinical features of CBD. Motor features. The motor fea-
tures of CBD emerged from early case series with
incomplete pathologic follow-up in which the CBS
presentation predominated, manifesting with asym-
metric onset of levodopa-resistant parkinsonism, dys-
tonia, and myoclonus. Seventy-three percent (72/99)
of reviewed patients with CBD with parkinsonism
had documented asymmetry. Limb rigidity (85%)
and bradykinesia (76%) were the most commonmotor
findings (table 1); 57% had limb rigidity and 48% had
bradykinesia at presentation (where described).
Although often characterized as severe, the nature of
limb rigidity was rarely described and may relate to
parkinsonism, dystonia, or gegenhalten/paratonia.
Axial rigidity was reported in 27% at presentation
and 69% at some time during the disease course.
CBD series emphasizing cognitive or behavioral pre-
sentations show low rates of early parkinsonism.13,15,20
Thirty-nine percent of CBD cases had tremor docu-
mented during the disease course (table 1), representing
a mix of resting, postural and action, and undefined
tremors. Tremor phenotype in CBD is poorly charac-
terized, but a CBS series suggests that it differs from the
typical rest tremor of Parkinson disease (PD).25 Low-
amplitude action myoclonus may resemble tremor.
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Gait abnormalities (often poorly characterized)
were described in 73% overall, but only in 33% at
onset, with postural instability and falls occurring at
similar frequencies (table 1). The timing of falls was
rarely described.
Sustained levodopa responsiveness—related to
parkinsonism—is an exclusion criterion in prior diag-
nostic schemes.4,5,9,10,26 Patients with CBD may dem-
onstrate transient mild to moderate improvement
with levodopa therapy and rarely develop levodopa-
induced dyskinesias,16 but a sustained response is rare.
The presence or absence of a levodopa response was
seldom described in compiled cases.
Dystonia is described in 59%–71% of patients in
series mixing CBS and CBD7,25,27; however, only
38% of compiled CBD cases ever had limb dystonia
(table 1) and only 20% presented with limb dystonia.
Clinical series describe myoclonus in 55%–93%
of patients with CBS,7,25,27,28 but myoclonus occurred
in only 27% of compiled CBD cases (table 1). Myoc-
lonus in CBD may be superimposed on dystonia18
and is most commonly described in the upper
extremities, but can also be present in the face.13,18
Descriptions include “focal myoclonus,”18 “stimulus-
sensitive myoclonus,”13,16 and “action myoclonus.”16
Studies of myoclonus in CBS suggest that a very short
latency may be characteristic,29,30 but it is unclear if
this is true in CBD.
Higher cortical features. Higher cortical features
described in CBD include apraxia, alien limb phe-
nomena, cortical sensory loss, cognitive impairment,
behavioral changes, and aphasia.
Apraxia is core to all previous diagnostic criteria
(table e-1). Limb apraxia was found in 57% of
compiled CBD cases (table 2). Ideomotor apraxia
is the most commonly described apraxia in
CBD15,16,18 with one series also describing limb-
kinetic apraxia.24 The presence of limb dystonia,
bradykinesia, and rigidity can make assessing ide-
omotor apraxia challenging and diagnosing limb-
kinetic apraxia impossible. Patients with CBD may
also have orobuccal apraxia or “apraxia of eyelid
opening,”13,15,16,18,21,24 though the latter is often a
misnomer representing pretarsal blepharospasm
rather than true apraxia.31
Alien limb phenomena are included in prior crite-
ria (table e-1), yet what behaviors constitute alien
limb phenomena remains a matter of debate.26 Alien
limb phenomena (including complex unintentional
limb movements interfering with normal tasks18 and
the sensation that a limb was foreign or had a will of
its own16) were described in 30% of compiled CBD
cases (table 2).
When reported (less than half of compiled CBD
cases), cortical sensory loss was present in approximately
a quarter of cases (table 2). Visual neglect occurs in
CBD,15,18,20 but also in Alzheimer disease (AD).20
Language impairments are now recognized as a com-
mon and frequently presenting feature of CBD. Aphasia
occurred in 40% of compiled CBD cases at presentation
and in 52% over the disease course (table 2). Reports
most commonly categorized the aphasia as primary pro-
gressive aphasia (PPA), progressive aphasia, or progress-
ive nonfluent aphasia (PNFA),15,20,32–34 though these
terms overlap and reflect older terminology that has
recently been revised.35 Aphasic patients with CBD
may progress to mutism.13,15,36 Apraxia of speech
(AOS) has also been described in CBD on its own
and coexisting with aphasia,20,32 though challenges in
diagnosing AOS limit efforts to estimate its frequency.
Some consider AOS a speech disorder rather than lan-
guage dysfunction37; consensus has been elusive. Speech
abnormalities in general were described in 53% of cases
(23% at presentation) (table 3). Some patients had dys-
arthria,18 but for others, few details were provided.13,15,21
Table 1 Frequency of motor features in available brain banks and studies with






Limb rigidity 65/114 (57) 153/180 (85)
Bradykinesia or clumsy limb 53/111 (48) 126/165 (76)
Postural instability 20/49 (41) 73/94 (78)
Falls 27/76 (36) 83/111 (75)
Abnormal gait 30/92 (33) 102/140 (73)
Axial rigidity 18/67 (27) 68/98 (69)
Tremorb 17/83 (20) 50/127 (39)
Limb dystonia 18/91 (20) 47/123 (38)
Myoclonus 14/94 (15) 34/128 (27)
a The denominator represents the total number of cases where it was mentioned whether or
not the feature in question was present. The total number of cases reviewed was 209, but
not all data had information on presenting signs.
b This may include some patients with myoclonus; repetitive myoclonic bursts in cortico-
basal degeneration may be mistaken for tremor.
Table 2 Frequency of higher cortical features in available brain banks and







Cognitive impairment (general) 59/114 (52) 123/175 (70)
Behavioral changes 52/113 (46) 82/150 (55)
Limb apraxia 46/102 (45) 81/142 (57)
Aphasia 40/101 (40) 80/155 (52)
Depression 21/80 (26) 42/82 (51)
Cortical sensory loss 20/81 (25) 29/107 (27)
Alien limb 20/90 (22) 24/81 (30)
a The denominator represents the total number of cases where it was mentioned whether or
not the feature in question was present. The total number of cases reviewed was 209, but
not all data had information on presenting signs.
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Over half of compiled CBD cases had cognitive
impairment at onset and 70% during the disease course
(table 2). While this represented patients’ subjective
memory concerns in some series, memory complaints
may relate to amnestic or nonamnestic (e.g., executive,
language) cognitive disturbances. Neuropsychological
testing in one study revealed that patients with CBD
had difficulties with learning tasks, word fluency, verbal
comprehension, perceptual organization, and cognitive
flexibility.38 Another study showed impairments in exec-
utive, language, and visuospatial domains with relatively
preserved episodic memory.15 In contrast, prominent
memory loss was a presenting symptom in one series
without neuropsychological testing.13 The presence of
memory impairment in CBD is underscored by numer-
ous series in which the clinical diagnoses of AD or atyp-
ical AD proved to be CBD.12,13,15,16,21,23,39 Acalculia and
visuospatial difficulties (with limited details) are rarely
described in CBD.15 Behavioral changes and executive
dysfunction are common in CBD, underscored by
many patients presenting with a behavioral variant fron-
totemporal dementia (FTD) syndrome.13,15,16,20,33,39–41
Symptoms include apathy, bizarre or antisocial behavior,
personality changes, irritability, disinhibition, and
hypersexuality.13,15,16,39 Fifty-five percent of reviewed
CBD cases had behavioral changes, often at presentation
(table 2). Clinical depression (rather than formal diag-
nosis) was described in 51% of patients where mood
was recorded (table 2), but this information was pro-
vided in less than half of cases. Only a single pub-
lished patient had hallucinations, coincident with
levodopa treatment,16 but hallucinations not associ-
ated with levodopa were also rarely described in brain
bank subjects (S.E. Lee and D.W. Dickson, personal
communications, 2011).
Other features. Eye movement abnormalities may be
present in CBD, but details are rarely provided and ter-
minology is often ambiguous. Sixty percent of com-
piled cases had eye movement abnormalities. At
onset, 33% showed such abnormalities (table 3). Stud-
ies of patients with CBS describe increased saccadic
latency,42–45 but this was not confirmed in a publica-
tion including oculographic measurements in 4 sub-
jects with CBD, where 3 had visually guided saccades
that were indistinguishable from normal controls.
Antisaccade performance was abnormal in all cases.46
Upper motor neuron signs are another feature
described in CBD cases (table 3), but since they also
occur in other atypical parkinsonisms, they are
unlikely to be a helpful distinguishing sign.
CBD phenotypes. Whereas clinical features were identi-
fied and extracted for the 209 CBD cases described
above, 267 CBD cases in the published literature and
available brain banks had information regarding clinical
diagnosis or phenotype. Of these 267 cases, data regard-
ing final diagnosis were available for 210 patients; 129
cases included information regarding initial diagnosis.
The 210 cases in brain banks and the litera-
ture13,15,16,21,23,39,41,47,48 with final clinical diagnoses
reported suggest 5 phenotypes associated with CBD
pathology, capturing 87.1% (183/210) of cases: CBS
(37.1%, 78/210), progressive supranuclear palsy syn-
drome (PSPS, also called Richardson syndrome)
(23.3%, 49/210, 2 described as atypical), FTD
(13.8%, 29/210), AD-like dementia (8.1%, 17/210
with 13 AD, 2 dementia, and 2 atypical dementia),
and aphasia (typically categorized as PPA or PNFA,
4.8%, 10/210). An additional 5.7% (12/210) were
mixed diagnoses involving these phenotypes. PD was
diagnosed in 3.8% (8/210, 1 described as atypical).
Two patients were diagnosed with dementia with Lewy
bodies (DLB) (D.W. Dickson, personal commu-
nication, 2011) and 3 patients received other diagnoses16
(K. Josephs, personal communication, 2011). Two pa-
tients received no syndromic diagnosis.
In the 129 patients in the brain banks and litera-
ture12,16,21,49,50 with initial clinical diagnoses described,
CBS was the most common presenting diagnosis
(27.1%, 35/129), followed by FTD and PD or atypical
PD (each 15.5%, 20/129), aphasia (14.7%, 19/129),
AD/dementia (9.3%, 12/129), and PSPS (6.2%,
8/129). The finding of PD as an early clinical diagnosis
and the difference in frequency between early and late
clinical diagnoses underscores the challenge in making
an accurate early diagnosis and the changing phenome-
nology over time.
Having identified CBD phenotypes, a literature
search was performed to identify clinical features from
clinicopathologic series that could help predict underly-
ing pathology given that the identified phenotypes also
have known associations with non-CBD pathologies.
Age. The combined mean (SD) age at CBD symp-
tom onset was 63.7 (7.0) years. Age at onset ranged
from 45 to 77.2 years.15,16,18,51
Disease duration. Mean CBD disease duration was
6.6 years (SD 2.4, range 2.0–12.5).15,18 In a series of
patients with rapidly progressive dementia, neither of
the patients with CBD died in the first year, in contrast
to the 8 patients with Creutzfeldt-Jakob disease (CJD)
(of 22 cases) who died within 12 months of onset.52
Table 3 Frequency of other features in available brain banks and studies with
‡5 pathologically confirmed corticobasal degeneration casesa
Feature At presentation, n (%) During entire course, n (%)
Abnormal eye movements 29/88 (33) 90/150 (60)
Hyperreflexia 17/57 (30) 58/116 (50)
Speech changes 18/77 (23) 59/112 (53)
a The denominator represents the total number of cases where it was mentioned whether or
not the feature in question was present. The total number of cases reviewed was 209, but
not all data had information on presenting signs.
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Family history. Most patients have no family history
of CBD. One series, however, reported a family history
of an FTD spectrum disorder in 2 of 14 patients with
CBD.15 Additionally, the tau mutation N296N has
resulted in pathology similar to CBD.53 Whether such
cases should be included with typical sporadic CBD
remains unclear. Currently, these rare familial CBD-like
disorders are the exception rather than the rule. Familial
CBS may be associated with granulin (GRN) mutations
and frontotemporal lobar degeneration with TDP-43
immunoreactive inclusions (FTLD-TDP) (i.e., non-
tau) pathology rather than with CBD.54–56
Comparison of phenotypes. Studies comparing the dif-
ferent CBD phenotypes are described in the supplemen-
tal text. No study conclusively identified clinical features
or imaging characteristics distinguishing CBD from
other pathologies. Potential differentiating features are
described in the supplemental text but require validation
with larger sample sizes.
Neuroimaging and laboratory markers. Few studies
evaluate imaging and laboratory markers in CBD. Stud-
ies using clinical cohorts report abnormalities consistent
with the topography of clinical findings rather than re-
flecting specific underlying pathology. Recently
described atrophy patterns in CBS associated with
CBD, progressive supranuclear palsy (PSP), AD, and
FTLD-TDP pathology57 are promising but require pro-
spective validation prior to inclusion in diagnostic crite-
ria. Imaging can help exclude other conditions with
CBS presentations, such as CJD. CSF biomarkers hold
promise but are not yet adequately studied in CBD. For
these reasons we have not currently proposed a labora-
tory-supported diagnostic category.
CBD diagnostic criteria. Given the complex clinicopath-
ologic correlations and varying phenotypes over
time,34,36 it is not surprising that developing CBD diag-
nostic criteria has proven challenging. Five potential
phenotypes were identified above, but while AD was a
common clinical misdiagnosis of CBD in compiled
cases, few details are available regarding how these diag-
noses were made and what features prompted this diag-
nosis. Given the relative frequencies of AD and CBD,
the false-positive diagnosis rate of an AD phenotype for
CBD would be high if this phenotype was included; it
was thus excluded. The 4 clinical phenotypes thought to
be most representative of CBD were CBS, frontal
behavioral-spatial syndrome, nonfluent/agrammatic var-
iant of primary progressive aphasia, and PSPS (table 4).
While these 4 phenotypes are frequent clinical pre-
sentations of CBD, it was difficult to identify specific
features that would consistently predict a CBD diagno-
sis vs other pathologic diagnoses such as FTLD or PSP
(supplemental text). Our deliberations led us to pro-
pose 2 diagnostic classifications for CBD (table 5): 1)
clinical research criteria for probable CBD (cr-CBD),
which attempt to maximize the chance of diagnosing
classic CBD without contamination from other pathol-
ogies; and 2) possible CBD criteria (p-CBD), which are
less restrictive but still emphasize presentations consis-
tent with underlying tau pathology. The p-CBD crite-
ria will catch more CBD cases but will also yield more
false-positives, including patients who also meet criteria
for other neurodegenerative conditions such as PSP.
This approach could be acceptable if research studies,
including experimental therapies, were directed at the
broader issue of tau-based pathology.
Both sets of criteria require insidious onset and grad-
ual progression with symptom duration of at least 1 year
to exclude rapidly progressive conditions more likely to
represent other pathologies (e.g., CJD). Age at onset
$50 years is required for cr-CBD given that this will
identify 98% of patients with CBD and exclude pathol-
ogies with younger age at onset (e.g., FTLD). No
age minimum is set for p-CBD, allowing for young-
onset familial cases of CBD related to tau mutations.
In addition, a family history (.1 relative) of a similar
neurodegenerative disease is an exclusion criterion for
cr-CBD but not p-CBD.
Accepted phenotypes are slightly different for the
2 sets of criteria. While PSPS is a CBD phenotype, it
is much more likely to represent PSP than CBD.58
Thus, PSPS is an acceptable phenotype only in the
p-CBD criteria. Features suggestive of idiopathic PD
(classic 4- to 6-Hz resting tremor, excellent and
Table 4 Proposed clinical phenotypes (syndromes) associated with the pathology of corticobasal degenerationa
Syndrome Features
Probable corticobasal syndrome Asymmetric presentation of 2 of: a) limb rigidity or akinesia, b) limb dystonia, c) limb myoclonus plus 2 of: d) orobuccal or
limb apraxia, e) cortical sensory deficit, f) alien limb phenomena (more than simple levitation)
Possible corticobasal syndrome May be symmetric: 1 of: a) limb rigidity or akinesia, b) limb dystonia, c) limb myoclonus plus 1 of: d) orobuccal or limb
apraxia, e) cortical sensory deficit, f) alien limb phenomena (more than simple levitation)
Frontal behavioral-spatial syndrome Two of: a) executive dysfunction, b) behavioral or personality changes, c) visuospatial deficits
Nonfluent/agrammatic variant of primary
progressive aphasia
Effortful, agrammatic speech plus at least one of: a) impaired grammar/sentence comprehension with relatively preserved
single word comprehension, or b) groping, distorted speech production (apraxia of speech)
Progressive supranuclear palsy syndrome Three of: a) axial or symmetric limb rigidity or akinesia, b) postural instability or falls, c) urinary incontinence, d) behavioral
changes, e) supranuclear vertical gaze palsy or decreased velocity of vertical saccades
aSee glossary of terms in appendix e-1 for further explanation of terms used.
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sustained levodopa response) are exclusion criteria for
both diagnostic criteria, as are hallucinations, which
are much more suggestive of PD or DLB than CBD.
Prominent dysautonomia and cerebellar signs are
thought to be more suggestive of multiple system atro-
phy than CBD and thus are exclusion criteria based on
consensus; CBD series do not routinely describe these
signs. Because of their association with non-tau pathol-
ogy (supplemental text), the presence of coincident
upper and lower motor neuron signs or semantic- or
logopenic-variant PPA are exclusion criteria for both cr-
CBD and p-CBD.
While tau mutations are allowed for p-CBD, GRN,
TDP-43, or FUS mutations are exclusions for both sets
of criteria. Because emerging research suggests that amy-
loid imaging and CSF Ab42/tau ratio may be useful in
diagnosing AD and these biomarkers have been incor-
porated into the 2011 AD diagnostic criteria,59 results
suggestive of AD on these studies are exclusion criteria
for CBD, acknowledging that we lack confirmation of
the ability of these tests to distinguish AD from CBD.
Mutations known to be associated with AD are also
exclusion criteria. Similarly, imaging studies suggestive
of other pathologies (e.g., CJD) are exclusions for CBD
diagnoses, but CBD-supportive imaging is not included
as a criterion given the need for further validation.
DISCUSSION Development of the proposed criteria
relied on expert consensus among behavioral neurology,
neuropsychology, and movement disorders specialists
and a critical review of brain bank and published clini-
cal–pathologic series. Limitations to the use of published
and brain bank series include their retrospective nature,
often relying on incomplete records, and subspecialty
biases in reporting centers. We attempted to minimize
these biases by strategically searching for cases, seeking
brain bank data where available, and maximizing the
sample size of the compiled cohort. Our decision to
only consider features as present or absent if specifically
described may result in overestimation of the frequency
of CBD features. Given the reliance on often incom-
plete retrospective data from a wide variety of sources,
this was thought to incur less bias than marking unde-
scribed features as absent. Our results should be inter-
preted with this limitation in mind. Furthermore, the
lower end of feature frequency can be calculated from
the provided tables and the total sample size of 209
cases.
Identifying clinical phenotypes and features specific
for CBD is an ongoing struggle limiting the ability to
create definitive clinical criteria. This is addressed by
proposing 2 sets of CBD criteria. Ultimately, a clear
diagnosis of CBDmay only be possible once biomarkers
and associated genetic mutations are identified. In the
meantime, the broader criteria may be useful, since
potential disease-modifying agents are likely to deal with
tauopathies as a class rather than considering tau-based
diagnoses separately.
Our understanding of CBD has grown tremen-
dously since its initial description but challenges with
clinical diagnosis remain. We propose new CBD diag-
nostic criteria based on recent advances and a review
of a large number of pathologically proven cases. We
expect that these criteria will need continued revisions
as our understanding of CBD improves and as imaging
studies and biomarkers advance and are validated for
distinguishing different phenotypes and diagnoses.
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